Time is on NVO and investors side. Good news on Saxenda and Liraglutide will likely keep the stock at high levels until the 2017 NovoLog patent expiration. Hopefully by then management will have a plan B for Tresbia including a plan for a strategic ...
Seeking Alpha · 4/5/2015
Large cap diabetes stocks Novo Nordisk A/S (NYSE ... Here is a quick wrap-up of what was important: MannKind Corporation Reports Earnings. On Tuesday, small cap MannKind Corporation reported earnings with fourth quarter operating expenses …
Smallcap Network · ByJohn Udovich · 2/26/2015
Stock analysts at Societe Generale initiated coverage on shares of Novo Nordisk A/S (NYSE:NVO) in a report issued on Wednesday, reports. The firm set a “sell” rating on the stock. Shares of Novo Nordisk A/S (NYSE:NVO) … · 4/15/2015
More from Bing News
Novo Nordisk (NYSE:NVO) stock rose sharply Friday after the Danish maker of diabetes therapies said it successfully completed a phase 2 trial for a new oral diabetes drug that could mark a milestone in diabetes therapy. The drug, called OG217SC ...
Investors Business Daily · ByVance Cariaga · 2/20/2015
Novo Nordisk A/S (NYSE:NVO) has received an average recommendation of “Hold” from the seven brokerages that are presently covering the company, Analyst Ratings reports. Two research analysts have rated the stock with a sell …
Mideast Times · 5/7/2015
The prices of China Mobile Ltd (CHL) shares have declined to close to the 52-week low of $60.94, which is 34.0% off the 52-week high of $96.50. China Mobile Ltd is owned by 11 Gurus we are tracking. Among them, 6 have added to their positions during the ...
Guru Focus · 8/23/2014
zulily, Inc. (ZU) of the Services sector is up 0.28% (change from open 0.93%) this morning trading at a volume of 444,847 shares and price of $10.85. zulily, Inc. (ZU)’s weekly performance is -15.14% and compared to their 52 week low, they are up 19.36%. · 5/7/2015
Societe Generale started coverage on shares of Novo Nordisk A/S (NYSE:NVO) in a research report sent to investors on Wednesday morning, reports. The firm issued a sell rating on the stock. Other equities research analysts have … · 4/18/2015
Here are 5 stocks in the Pharmaceuticals industry ranked by performance ... ranks third with a loss of 2.39%. Novo Nordisk (NYSE:NVO) follows with a loss of 1.84% and AstraZeneca (NYSE:AZN) rounds out the bottom five with a loss of 1.53%.
Financial News Network Online · ByAdrienne Chilton · 4/14/2015
Although the earnings season is coming to a close, few companies are yet to report their results. Late last week, Novo Nordisk A/S (NVO - Analyst Report) reported first-quarter 2015 earnings of 57 cents per American Depositary Receipt, beating the Zacks ...
ZACKS · 5/4/2015